In this task, you are given a summary for US Congressional and California state bill, your task is to generate a Title for this bill. The preferred titles are under forty words and mention the purpose of the bill.

Example Input: War Funding Accountability Act - Requires the President, within 30 days of enactment of an appropriations Act that funds military operations or reconstruction in Iraq, to prepare and transmit to Congress a report (as well as subsequent progress reports) detailing U.S. goals with respect to such operations or reconstruction efforts, including: (1) a description of the purposes for which amounts will be made available; (2) a plan for the security of Iraq including a plan to ensure participation by the armed forces of additional countries in Iraq; (3) a plan for the reconstruction of Iraq; (4) a description of progress toward elections for a permanent Iraqi government; and (5) a description of U.S. efforts to obtain financial support for Iraq from other countries and international financial institutions.

Requires the President, under the same time period and with similar plan requirements as above, to prepare and transmit to Congress a report (as well as subsequent reports) detailing U.S. goals with respect to military operations or reconstruction efforts in Afghanistan.

States that if the requirements to transmit such initial or subsequent reports are not met, then unobligated or unexpended amounts for reconstruction with respect to the subject of such reports may not be obligated or expended until transmittal to Congress.
Example Output: To establish reporting requirements relating to funds made available for military operations in Iraq or the reconstruction of Iraq and for military operations in Afghanistan or the reconstruction of Afghanistan, and for other purposes.

Example Input: Amends the Federal Food, Drug, and Cosmetic Act to require license applications for new drugs and biological products to assess such drug's or product's safety and effectiveness for relevant pediatric subpopulations, including dosage.Permits extrapolation from adult studies where the course of the disease and the effects of the drug are sufficiently similar in all populations.Permits deferral of such assessments if adult studies are completed earlier and the applicant submits a plan for or a description of planned or ongoing pediatric studies.Permits full waiver of such assessments if: (1) studies are highly impractical or impossible; (2) the evidence strongly suggests that the drug or product would be ineffective or unsafe in all pediatric age groups; (3) there is no meaningful therapeutic advantage or benefit in the pediatric population; or (4) the drug or product is not likely to be used in a substantial number of pediatric patients.Permits partial waivers at the request of an applicant for a specific pediatric subpopulation if any of the full waiver grounds apply to that subpopulation or reasonable attempts for a pediatric formulation for that subpopulation have failed.Requires labels to provide indication in cases in which a waiver has been granted due to evidence a product would be unsafe or ineffective in pediatric populations.Authorizes the Secretary of Health and Human Services to specify a date for submission of pediatric assessments if: (1) the drug or biological product would represent a meaningful therapeutic benefit for pediatric patients for one or more claimed indications and the absence of adequate labeling could pose significant risks to pediatric patients; or (2) it is used for a number of pediatric patients for the labeled indications and the absence of adequate labeling could pose significant risks to pediatric patients. Sets forth criteria for full waiver and partial waivers of such requirement. Requires labels to provide indication in cases in which a waiver has been granted due to evidence a product would be unsafe or ineffective in pediatric populations.Requires the Secretary to issue a written request for related pediatric studies under the Public Health Service Act before requiring an assessment for a drug.States that drugs or products with delayed assessments may be deemed misbranded and subject to seizure and injunctive proceedings, though not penalties.
Example Output: To amend the Federal Food, Drug, and Cosmetic Act to require labeling containing information applicable to pediatric patients.

Example Input: Community Disease Cluster Assistance Act - Authorizes the Administrator of the Environmental Protection Agency (EPA), in coordination with the Secretary of Health and Human Services (HHS), to award grants to any individual or group of individuals that may be affected by a reported community-based disease cluster. Requires such grants to be used to obtain technical assistance in interpreting information regarding: (1) investigating such reported disease clusters associated with hazardous chemicals, (2) the potential hazardous chemicals associated with a reported disease cluster, (3) providing individuals or groups with community-based tools to educate them about the mitigation of hazardous chemicals associated with reported disease clusters, or (4) other scientific and technical issues related to reported disease clusters.
Example Output:
Community Disease Cluster Assistance Act